VivoSeq
Cardiovascular

Vascular Access

0

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Vascular Access is an early-stage landscape with 0 programs across 3 companies. The most active players are ARCA Biopharma, Inc., Bristol-Myers Squibb, ZARS Pharma Inc..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

ARCA Biopharma, Inc.

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalZ

ZARS Pharma Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Completed6 · 50%
Unknown status4 · 33%
Terminated1 · 8%
Enrolling by invitation1 · 8%

Clinical Trials

Trial Activity

12 trials

The Effect of Stress Ball Application During Port Catheter Needle Change on Pain, Anxiety, and Patient Satisfaction: A Randomized Controlled Study
Enrolling by invitation·KKahramanmaras Sutcu Imam University·Preclinical·NCT07679295·50 enrolled
Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices
Completed·AARCA Biopharma, Inc.·Phase 2·NCT00073515·115 enrolled
Buzzy Plus EMLA Cream for Vascular Access in Children
Completed·IIRCCS Burlo Garofolo·N/A·NCT04695054·94 enrolled
Comparison of Vascular Access for Radial and Femoral Completion of Diagnostic Cardiac Catheterization
Completed·CCentro Cardiológico del Caribe, Columbia·Phase 3·NCT01984411·220 enrolled
Sirolimus Use in Angioplasty for Vascular Access Extension
Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT01595841·17 enrolled
Ascorbic Acid on Restenosis of Dysfunctional Hemodialysis Vascular Access
Completed·NNational Taiwan University Hospital Hsin-Chu Branch·Phase 2·NCT03524846·93 enrolled
S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Vascular Access Procedures in Children
Completed·ZZARS Pharma Inc.·Phase 3·NCT00125255·81 enrolled
Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis
Terminated·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT00249002·9 enrolled
Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access
Unknown status·NNational Taiwan University Hospital Hsin-Chu Branch·Phase 4·NCT04489849·150 enrolled
Antiaggregation in Primary Prevention of Vascular Access for Hemodialysis
Unknown status·TTunis University·Phase 4·NCT02055131·300 enrolled
Ethanol Lock for the Salvage of Infected Long-term Vascular Access
Unknown status·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 3·NCT01186172·200 enrolled
Platelet Activation Affecting the Rate of Vascular Access Patency
Unknown status·KKorea University Anam Hospital·N/A·NCT05165797·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)